Screener / SEC EDGAR /CIK 0000874015 /10-K filed Feb 26, 2026, compared with Feb 19, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Ionis Pharmaceuticals Inc IONS

Compare with peers Embed

IONS among the 162 companies we cover

Where it stands · the better end on the right. The band holds the middle half; the line is the median.

All 162
Sales growth
+4.8%+20.2%
+33.8%26th of 155 · median +10.5%
Net margin
-4.1%15.3%
-56.9%139th of 154 · median 6.8%
Return on equity
-5.2%18.5%
-138.8%142nd of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
-64.2%134th of 145 · median 10.0%
Debt / equity (less is better)
1.160.42
4.60106th of 108 · median 0.69

IONS and 9 peers, year by year

The 9 Health care companies closest to IONS in revenue over the last twelve months. Every number is from the 10-K and links to it in SEC's Inline XBRL viewer.

Choose the peers

Health care companies (up to 9):

Each company's latest fiscal year
CompanyYearRevenueSales growthGross marginOperating marginNet marginFCF marginReturn on equityDebt / equity
IONS Ionis Pharmaceuticals Inc FY2025 $943.7M+33.8%-−40.4%−40.4%−33.9%−78.0%3.71
BCRX Biocryst Pharmaceuticals Inc FY2025 $874.8M+94.1%-39.0%30.2%39.4%n/mn/m
CORT Corcept Therapeutics Inc FY2025 $761.4M+12.8%-5.9%13.1%18.6%15.4%-
BBIO BridgeBio Pharma, Inc. FY2025 $502.1M+126%-−104.2%−144.4%−89.0%n/mn/m
WRBY Warby Parker Inc. FY2025 $871.9M+13.0%54.0%−0.6%0.2%5.0%0.4%-
TGTX TG Therapeutics, Inc. FY2025 $616.3M+87.3%-20.0%72.6%−4.1%69.0%0.38
INSP Inspire Medical Systems, Inc. FY2025 $912.0M+13.6%85.4%5.6%15.9%8.6%18.6%-
CAI Caris Life Sciences, Inc. FY2025 $812.0M+97.0%-5.6%−8.4%8.2%−11.8%0.66
AXSM Axsome Therapeutics, Inc. FY2025 $638.5M+65.5%-−26.1%−28.7%−14.7%n/m2.13
SUPN Supernus, Inc. FY2025 $719.0M+8.6%-−8.7%−5.4%6.4%−3.6%-

Each company, year by year

Bars: revenue, each company on its own scale. Line: net margin, on one scale for all. FY2016 to FY2025 · 10-K XBRL

IONSIonis Pharmaceuticals Inc
FY2016 revenue $372.8MFY2017 revenue $514.2MFY2018 revenue $599.7MFY2019 revenue $1.1BFY2020 revenue $729.3MFY2021 revenue $810.5MFY2022 revenue $587.4MFY2023 revenue $787.6MFY2024 revenue $705.1MFY2025 revenue $943.7M FY2016 net margin −16.2%FY2017 net margin 0.1%FY2018 net margin 45.6%FY2019 net margin 24.8%FY2020 net margin −60.9%FY2021 net margin −3.5%FY2022 net margin −45.9%FY2023 net margin −46.5%FY2024 net margin −64.4%FY2025 net margin −40.4% FY2016FY2025
Revenue$943.7M Growth+33.8% Net margin−40.4%
BCRXBiocryst Pharmaceuticals Inc
FY2016 revenue $26.4MFY2017 revenue $25.2MFY2018 revenue $20.7MFY2019 revenue $48.8MFY2020 revenue $17.8MFY2021 revenue $157.2MFY2022 revenue $270.8MFY2023 revenue $331.4MFY2024 revenue $450.7MFY2025 revenue $874.8M FY2016 net margin −209.3%FY2017 net margin −261.2%FY2018 net margin −490.3%FY2019 net margin −223.0%FY2021 net margin −117.1%FY2022 net margin −91.2%FY2023 net margin −68.4%FY2024 net margin −19.7%FY2025 net margin 30.2% FY2016FY2025
Revenue$874.8M Growth+94.1% Net margin30.2%
CORTCorcept Therapeutics Inc
FY2016 revenue $81.3MFY2017 revenue $159.2MFY2018 revenue $251.2MFY2019 revenue $306.5MFY2020 revenue $353.9MFY2021 revenue $366.0MFY2022 revenue $401.9MFY2023 revenue $482.4MFY2024 revenue $675.0MFY2025 revenue $761.4M FY2016 net margin 10.0%FY2017 net margin 81.1%FY2018 net margin 30.0%FY2019 net margin 30.7%FY2020 net margin 30.0%FY2021 net margin 30.7%FY2022 net margin 25.2%FY2023 net margin 22.0%FY2024 net margin 20.9%FY2025 net margin 13.1% FY2016FY2025
Revenue$761.4M Growth+12.8% Net margin13.1%
BBIOBridgeBio Pharma, Inc.
FY2019 revenue $40.6MFY2020 revenue $8.2MFY2021 revenue $69.7MFY2022 revenue $77.6MFY2023 revenue $9.3MFY2024 revenue $221.9MFY2025 revenue $502.1M FY2019 net margin −642.5%FY2021 net margin −806.9%FY2022 net margin −619.7%FY2024 net margin −241.4%FY2025 net margin −144.4% FY2016FY2025
Revenue$502.1M Growth+126% Net margin−144.4%
WRBYWarby Parker Inc.
FY2019 revenue $370.5MFY2020 revenue $393.7MFY2021 revenue $540.8MFY2022 revenue $598.1MFY2023 revenue $669.8MFY2024 revenue $771.3MFY2025 revenue $871.9M FY2019 net margin 0.0%FY2020 net margin −14.2%FY2021 net margin −26.7%FY2022 net margin −18.5%FY2023 net margin −9.4%FY2024 net margin −2.6%FY2025 net margin 0.2% FY2016FY2025
Revenue$871.9M Growth+13.0% Net margin0.2%
TGTXTG Therapeutics, Inc.
FY2016 revenue $152KFY2017 revenue $152KFY2018 revenue $152KFY2019 revenue $152KFY2020 revenue $152KFY2021 revenue $6.7MFY2022 revenue $2.8MFY2023 revenue $233.7MFY2024 revenue $329.0MFY2025 revenue $616.3M FY2023 net margin 5.4%FY2024 net margin 7.1%FY2025 net margin 72.6% FY2016FY2025
Revenue$616.3M Growth+87.3% Net margin72.6%
INSPInspire Medical Systems, Inc.
FY2016 revenue $16.4MFY2017 revenue $28.6MFY2018 revenue $50.6MFY2019 revenue $82.0MFY2020 revenue $115.4MFY2021 revenue $233.4MFY2022 revenue $407.9MFY2023 revenue $624.8MFY2024 revenue $802.8MFY2025 revenue $912.0M FY2016 net margin −112.8%FY2017 net margin −61.3%FY2018 net margin −43.1%FY2019 net margin −40.5%FY2020 net margin −49.6%FY2021 net margin −18.0%FY2022 net margin −11.0%FY2023 net margin −3.4%FY2024 net margin 6.7%FY2025 net margin 15.9% FY2016FY2025
Revenue$912.0M Growth+13.6% Net margin15.9%
CAICaris Life Sciences, Inc.
FY2023 revenue $306.1MFY2024 revenue $412.3MFY2025 revenue $812.0M FY2023 net margin −111.5%FY2024 net margin −68.4%FY2025 net margin −8.4% FY2016FY2025
Revenue$812.0M Growth+97.0% Net margin−8.4%
AXSMAxsome Therapeutics, Inc.
FY2022 revenue $50.0MFY2023 revenue $270.6MFY2024 revenue $385.7MFY2025 revenue $638.5M FY2022 net margin −374.0%FY2023 net margin −88.4%FY2024 net margin −74.5%FY2025 net margin −28.7% FY2016FY2025
Revenue$638.5M Growth+65.5% Net margin−28.7%
SUPNSupernus, Inc.
FY2016 revenue $215.0MFY2017 revenue $302.2MFY2018 revenue $408.9MFY2019 revenue $392.8MFY2020 revenue $520.4MFY2021 revenue $579.8MFY2022 revenue $667.2MFY2023 revenue $607.5MFY2024 revenue $661.8MFY2025 revenue $719.0M FY2016 net margin 42.4%FY2017 net margin 19.0%FY2018 net margin 27.1%FY2019 net margin 28.8%FY2020 net margin 24.4%FY2021 net margin 9.2%FY2022 net margin 9.1%FY2023 net margin 0.2%FY2024 net margin 11.2%FY2025 net margin −5.4% FY2016FY2025
Revenue$719.0M Growth+8.6% Net margin−5.4%

Who rewrote the most

Share of the words changed in Risk Factors and in MD&A, latest 10-K against the one before

Risk FactorsMD&AEach company's latest 10-K, so the dates differ. A company that rewrote much may have reorganized the text.

Revenue, FY2016 to FY2025

Revenue as reported in the 10-K.

$0 $1.1B FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 BCRX: $26.4M, $25.2M, $20.7M, $48.8M, $17.8M, $157.2M, $270.8M, $331.4M, $450.7M, $874.8M BCRX CORT: $81.3M, $159.2M, $251.2M, $306.5M, $353.9M, $366.0M, $401.9M, $482.4M, $675.0M, $761.4M CORT BBIO: -, -, -, $40.6M, $8.2M, $69.7M, $77.6M, $9.3M, $221.9M, $502.1M BBIO WRBY: -, -, -, $370.5M, $393.7M, $540.8M, $598.1M, $669.8M, $771.3M, $871.9M WRBY TGTX: $152K, $152K, $152K, $152K, $152K, $6.7M, $2.8M, $233.7M, $329.0M, $616.3M TGTX INSP: $16.4M, $28.6M, $50.6M, $82.0M, $115.4M, $233.4M, $407.9M, $624.8M, $802.8M, $912.0M INSP CAI: -, -, -, -, -, -, -, $306.1M, $412.3M, $812.0M CAI AXSM: -, -, -, -, $0, $0, $50.0M, $270.6M, $385.7M, $638.5M AXSM SUPN: $215.0M, $302.2M, $408.9M, $392.8M, $520.4M, $579.8M, $667.2M, $607.5M, $661.8M, $719.0M SUPN IONS: $372.8M, $514.2M, $599.7M, $1.1B, $729.3M, $810.5M, $587.4M, $787.6M, $705.1M, $943.7M IONS
IONS is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from $0 to $1.1B. A gap is a year with no number. A ring marks where a line starts: BBIO, WRBY, CAI, AXSM have no earlier 10-K here.

Sales growth, FY2016 to FY2025

Revenue against the fiscal year before.

−88.0% +782% FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 BCRX: −45.4%, −4.4%, −18.0%, +136%, −63.5%, +782%, +72.3%, +22.4%, +36.0%, +94.1% BCRX CORT: +61.7%, +95.8%, +57.8%, +22.0%, +15.5%, +3.4%, +9.8%, +20.0%, +39.9%, +12.8% CORT BBIO: -, -, -, -, −79.7%, +745%, +11.4%, −88.0%, n/m, +126% BBIO WRBY: -, -, -, -, +6.3%, +37.4%, +10.6%, +12.0%, +15.2%, +13.0% WRBY TGTX: -, 0.0%, 0.0%, 0.0%, 0.0%, n/m, −58.4%, n/m, +40.8%, +87.3% TGTX INSP: -, +73.9%, +77.1%, +62.2%, +40.6%, +102%, +74.7%, +53.2%, +28.5%, +13.6% INSP CAI: -, -, -, -, -, -, -, -, +34.7%, +97.0% CAI AXSM: -, -, -, -, -, -, -, +441%, +42.5%, +65.5% AXSM SUPN: +45.8%, +40.6%, +35.3%, −3.9%, +32.5%, +11.4%, +15.1%, −8.9%, +8.9%, +8.6% SUPN IONS: +22.2%, +37.9%, +16.6%, +87.2%, −35.0%, +11.1%, −27.5%, +34.1%, −10.5%, +33.8% IONS
IONS is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −88.0% to +782%. A gap is a year with no number. A ring marks where a line starts: BBIO, WRBY, TGTX, INSP, CAI, AXSM have no earlier 10-K here.

Gross margin, FY2016 to FY2025

Gross profit / revenue.

54.0% 85.7% FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 WRBY: -, -, -, 60.2%, 58.9%, 58.8%, 57.0%, 54.5%, 55.3%, 54.0% WRBY INSP: 76.2%, 78.9%, 80.1%, 83.4%, 84.7%, 85.7%, 83.8%, 84.5%, 84.7%, 85.4% INSP
IONS is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from 54.0% to 85.7%. A gap is a year with no number. A ring marks where a line starts: WRBY has no earlier 10-K here.
CompanyFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
IONS Dec ----------
BCRX Dec ----------
CORT Dec ----------
BBIO Dec ----------
WRBY Dec ---60.2%58.9%58.8%57.0%54.5%55.3%54.0%
TGTX Dec ----------
INSP Dec 76.2%78.9%80.1%83.4%84.7%85.7%83.8%84.5%84.7%85.4%
CAI Dec ----------
AXSM Dec ----------
SUPN Dec ----------
Peer median----------

Operating margin, FY2016 to FY2025

Operating income / revenue.

−981.1% 39.0% FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 BCRX: −184.4%, −227.9%, −456.2%, −203.7%, −981.1%, −113.1%, −54.8%, −31.3%, −0.6%, 39.0% BCRX CORT: 12.5%, 33.2%, 35.6%, 36.4%, 36.2%, 34.0%, 28.0%, 22.2%, 20.3%, 5.9% CORT BBIO: -, -, -, −656.4%, n/m, −827.1%, −659.6%, n/m, −267.2%, −104.2% BBIO WRBY: -, -, -, −0.4%, −14.1%, −26.6%, −18.6%, −10.7%, −3.9%, −0.6% WRBY TGTX: n/m, n/m, n/m, n/m, n/m, n/m, n/m, 8.8%, 12.7%, 20.0% TGTX INSP: −105.0%, −56.0%, −40.3%, −42.5%, −48.7%, −17.1%, −11.7%, −6.4%, 4.5%, 5.6% INSP CAI: -, -, -, -, -, -, -, −104.4%, −62.4%, 5.6% CAI AXSM: -, -, -, -, -, -, −359.3%, −85.7%, −72.7%, −26.1% AXSM SUPN: 25.2%, 32.9%, 35.3%, 37.8%, 33.4%, 14.8%, 6.9%, −0.9%, 12.3%, −8.7% SUPN IONS: −5.4%, 6.0%, −10.2%, 32.6%, −23.6%, −3.7%, −69.8%, −44.9%, −67.4%, −40.4% IONS
IONS is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −981.1% to 39.0%. A gap is a year with no number. A ring marks where a line starts: BBIO, WRBY, TGTX, CAI, AXSM have no earlier 10-K here.

Net margin, FY2016 to FY2025

Net income / revenue.

−806.9% 81.1% FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 BCRX: −209.3%, −261.2%, −490.3%, −223.0%, n/m, −117.1%, −91.2%, −68.4%, −19.7%, 30.2% BCRX CORT: 10.0%, 81.1%, 30.0%, 30.7%, 30.0%, 30.7%, 25.2%, 22.0%, 20.9%, 13.1% CORT BBIO: -, -, -, −642.5%, n/m, −806.9%, −619.7%, n/m, −241.4%, −144.4% BBIO WRBY: -, -, -, 0.0%, −14.2%, −26.7%, −18.5%, −9.4%, −2.6%, 0.2% WRBY TGTX: n/m, n/m, n/m, n/m, n/m, n/m, n/m, 5.4%, 7.1%, 72.6% TGTX INSP: −112.8%, −61.3%, −43.1%, −40.5%, −49.6%, −18.0%, −11.0%, −3.4%, 6.7%, 15.9% INSP CAI: -, -, -, -, -, -, -, −111.5%, −68.4%, −8.4% CAI AXSM: -, -, -, -, -, -, −374.0%, −88.4%, −74.5%, −28.7% AXSM SUPN: 42.4%, 19.0%, 27.1%, 28.8%, 24.4%, 9.2%, 9.1%, 0.2%, 11.2%, −5.4% SUPN IONS: −16.2%, 0.1%, 45.6%, 24.8%, −60.9%, −3.5%, −45.9%, −46.5%, −64.4%, −40.4% IONS
IONS is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −806.9% to 81.1%. A gap is a year with no number. A ring marks where a line starts: BBIO, WRBY, TGTX, CAI, AXSM have no earlier 10-K here.

Free cash flow, FY2016 to FY2025

Cash from operations minus capital spending.

−$546.2M $589.3M FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 BCRX: −$58.7M, −$41.5M, −$92.9M, −$89.9M, −$135.6M, −$144.5M, −$163.2M, −$97.3M, −$53.1M, $344.9M BCRX CORT: $18.2M, $60.5M, $115.4M, $135.0M, $150.7M, $167.4M, $119.9M, $126.5M, $196.1M, $141.8M CORT BBIO: -, −$41.0M, −$138.8M, −$256.2M, −$407.2M, −$511.2M, −$424.3M, −$529.0M, −$521.7M, −$447.0M BBIO WRBY: -, -, -, −$11.2M, $12.7M, −$80.5M, −$49.8M, $7.3M, $34.7M, $43.7M WRBY TGTX: −$61.9M, −$93.8M, −$129.0M, −$132.9M, −$214.9M, −$296.0M, −$176.2M, −$31.4M, −$40.6M, −$25.0M TGTX INSP: −$18.3M, −$16.2M, −$18.9M, −$35.6M, −$55.5M, −$24.8M, $2.5M, $1.0M, $91.1M, $78.5M INSP CAI: -, -, -, -, -, -, -, −$298.4M, −$253.6M, $66.9M CAI AXSM: −$21.4M, −$26.5M, −$30.1M, −$46.4M, −$78.5M, −$108.5M, −$117.2M, −$145.7M, −$128.7M, −$93.9M AXSM SUPN: $65.2M, $112.6M, $128.1M, $140.4M, $134.9M, -, $116.4M, $110.5M, $171.2M, $46.0M SUPN IONS: −$119.2M, $139.4M, $589.3M, $314.7M, $772K, $18.8M, −$290.1M, −$331.3M, −$546.2M, −$320.0M IONS
IONS is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −$546.2M to $589.3M. A gap is a year with no number. A ring marks where a line starts: BBIO, WRBY, CAI have no earlier 10-K here.

FCF margin, FY2016 to FY2025

Free cash flow / revenue.

−761.4% 98.3% FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 BCRX: −222.8%, −164.7%, −450.0%, −184.1%, −761.4%, −92.0%, −60.3%, −29.4%, −11.8%, 39.4% BCRX CORT: 22.4%, 38.0%, 45.9%, 44.1%, 42.6%, 45.7%, 29.8%, 26.2%, 29.1%, 18.6% CORT BBIO: -, -, -, −631.7%, n/m, −733.2%, −546.5%, n/m, −235.1%, −89.0% BBIO WRBY: -, -, -, −3.0%, 3.2%, −14.9%, −8.3%, 1.1%, 4.5%, 5.0% WRBY TGTX: n/m, n/m, n/m, n/m, n/m, n/m, n/m, −13.4%, −12.3%, −4.1% TGTX INSP: −111.1%, −56.7%, −37.4%, −43.4%, −48.1%, −10.6%, 0.6%, 0.2%, 11.4%, 8.6% INSP CAI: -, -, -, -, -, -, -, −97.5%, −61.5%, 8.2% CAI AXSM: -, -, -, -, -, -, −234.3%, −53.8%, −33.4%, −14.7% AXSM SUPN: 30.3%, 37.3%, 31.3%, 35.7%, 25.9%, -, 17.4%, 18.2%, 25.9%, 6.4% SUPN IONS: −32.0%, 27.1%, 98.3%, 28.0%, 0.1%, 2.3%, −49.4%, −42.1%, −77.5%, −33.9% IONS
IONS is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −761.4% to 98.3%. A gap is a year with no number. A ring marks where a line starts: BBIO, WRBY, TGTX, CAI, AXSM have no earlier 10-K here.

Return on equity, FY2016 to FY2025

Net income / shareholders' equity at the year end.

−176.8% 69.0% FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 BCRX: n/m, −78.5%, n/m, n/m, n/m, n/m, n/m, n/m, n/m, n/m BCRX CORT: 19.7%, 67.6%, 27.3%, 25.4%, 20.3%, 29.9%, 20.2%, 20.9%, 20.8%, 15.4% CORT BBIO: -, −35.6%, −41.5%, −63.8%, n/m, n/m, n/m, n/m, n/m, n/m BBIO WRBY: -, -, -, n/m, n/m, −50.4%, −38.5%, −20.9%, −6.0%, 0.4% WRBY TGTX: n/m, −176.8%, n/m, n/m, −53.8%, −146.8%, n/m, 7.9%, 10.5%, 69.0% TGTX INSP: n/m, n/m, −13.3%, −23.8%, −24.9%, −18.4%, −9.0%, −3.7%, 7.8%, 18.6% INSP CAI: -, -, -, -, -, -, -, n/m, n/m, −11.8% CAI AXSM: −126.1%, −173.1%, n/m, −38.2%, −90.4%, n/m, −170.8%, −125.3%, n/m, n/m AXSM SUPN: 47.6%, 21.4%, 24.5%, 19.0%, 17.0%, 6.5%, 6.9%, 0.1%, 7.1%, −3.6% SUPN IONS: −60.7%, 0.1%, 26.1%, 18.9%, −59.8%, −3.7%, −47.1%, −94.7%, −77.1%, −78.0% IONS
IONS is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −176.8% to 69.0%. A gap is a year with no number. A ring marks where a line starts: BCRX, BBIO, WRBY, TGTX, INSP, CAI have no earlier 10-K here.

Debt / equity, FY2016 to FY2025

Total debt / shareholders' equity at the year end.

0.00 14.58 FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 BCRX: 14.58, 0.27, 0.61, 1.31, n/m, n/m, n/m, n/m, n/m, n/m BCRX CORT: 0.35, 0.00, -, -, -, -, -, -, -, - CORT BBIO: -, -, 0.17, 0.23, 1.62, n/m, n/m, n/m, n/m, n/m BBIO TGTX: 0.00, 0.00, 0.00, 0.75, 0.06, 0.29, 1.21, 0.63, 1.10, 0.38 TGTX INSP: -, 12.40, 0.15, 0.18, 0.11, 0.11, 0.00, -, -, - INSP CAI: -, -, -, -, -, -, -, -, n/m, 0.66 CAI AXSM: 0.45, 0.59, 7.37, 0.11, 0.42, 3.14, 0.86, 0.93, 3.17, 2.13 AXSM SUPN: -, -, -, -, -, 0.46, -, -, -, - SUPN IONS: -, -, -, 0.54, 1.13, -, 2.08, 3.38, 2.13, 3.71 IONS
IONS is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from 0.00 to 14.58. A gap is a year with no number. A ring marks where a line starts: IONS, BBIO, INSP, CAI, SUPN have no earlier 10-K here.
CompanyFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
IONS Dec ---0.541.13-2.083.382.133.71
BCRX Dec 14.580.270.611.31n/mn/mn/mn/mn/mn/m
CORT Dec 0.350.00--------
BBIO Dec --0.170.231.62n/mn/mn/mn/mn/m
WRBY Dec ----------
TGTX Dec 0.000.000.000.750.060.291.210.631.100.38
INSP Dec -12.400.150.180.110.110.00---
CAI Dec --------n/m0.66
AXSM Dec 0.450.597.370.110.423.140.860.933.172.13
SUPN Dec -----0.46----
Peer median0.400.270.170.230.270.380.86--0.66

EPS (diluted), FY2016 to FY2025

Diluted earnings per share, on today's share count after splits.

−$940.00 $4.89 FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 BCRX: −$0.75, −$0.78, −$0.98, −$940.00, −$1.09, −$1.03, −$1.33, −$1.18, −$0.43, $1.21 BCRX CORT: $0.07, $1.04, $0.60, $0.77, $0.85, $0.89, $0.87, $0.94, $1.23, $0.82 CORT BBIO: -, −$1.00, −$2.12, −$2.48, −$3.80, −$3.90, −$3.26, −$3.95, −$2.88, −$3.78 BBIO WRBY: -, -, -, −$1.10, −$1.05, −$2.21, −$0.96, −$0.54, −$0.17, $0.01 WRBY TGTX: −$1.60, −$1.91, −$2.30, −$1.96, −$2.42, −$2.63, −$1.65, $0.09, $0.15, $2.77 TGTX INSP: −$16.90, −$14.88, −$1.50, −$1.40, −$2.19, −$1.54, −$1.60, −$0.72, $1.75, $4.89 INSP CAI: -, -, -, -, -, -, -, −$13.24, −$10.66, −$3.22 CAI AXSM: −$1.42, −$1.27, −$1.15, −$2.01, −$2.77, −$3.47, −$4.60, −$5.27, −$5.99, −$3.68 AXSM SUPN: $1.76, $1.08, $2.05, $2.10, $2.36, $0.98, $1.04, $0.02, $1.32, −$0.68 SUPN IONS: −$0.50, $0.15, $2.07, $1.90, −$3.18, −$0.20, −$1.90, −$2.56, −$3.04, −$2.38 IONS
IONS is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −$940.00 to $4.89. A gap is a year with no number. A ring marks where a line starts: BBIO, WRBY, CAI have no earlier 10-K here.

Fiscal years are lined up as each company's 10-K names them; the month next to a ticker is when its year ends. Hover a number for the XBRL line items and the filing; click it to open the filing on sec.gov. "n/m" means not meaningful: equity below zero, or a base so close to zero that the ratio says nothing. The peer median leaves out IONS and needs at least three peers with the number. P/E, P/S and P/FCF at each year end appear here once the site has daily prices. What the same companies write about AI, tariffs and more

Sources

Each company's 10-K, from SEC's XBRL company facts. Every number links to its filing in the Inline XBRL viewer.

Also

Financials: IONS's own statements, year by year. Compare: the whole peer group on one page.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/IONS/export.csv") into a cell.

Next:Industry numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.